Literature DB >> 14576821

Breast cancer-specific gene 1 interacts with the mitotic checkpoint kinase BubR1.

Anu Gupta1, Satoru Inaba, Oi Kwan Wong, Guowei Fang, Jingwen Liu.   

Abstract

The abnormal expression of breast cancer-specific gene 1 (BCSG1) in malignant mammary epithelial cells is highly associated with the development and progression of breast cancer. A series of in vitro and in vivo studies performed in our laboratory and others have demonstrated that BCSG1 expression significantly stimulates proliferation, invasion, and metastasis of breast cancer cells. However, currently little is known about how BCSG1 exerts its oncogenic functions. To elucidate the cellular mechanisms underlying the effects of BCSG1 in breast cancer cells, we used a yeast two-hybrid system to screen for proteins that could associate with BCSG1. Through this screening, we identified the mitotic checkpoint protein BubR1 as a novel binding partner of BCSG1. The specific association of BCSG1 with BubR1 in breast cancer cells was demonstrated by immunoprecipitation and GST pull-down assays. Intriguingly, experiments conducted in four different cell lines all showed that exogenous expressions of BCSG1 consistently reduce the cellular levels of the BubR1 protein without affecting BubR1 mRNA expression. The tendency of endogenous BCSG1 expression coinciding with lower BubR1 protein levels was also observed in seven out of eight breast cancer cell lines. We further showed that the reducing effect of BCSG1 on BubR1 protein expression could be prevented by treating BCSG1-transfected cells with MG-132, a selective 26S proteasome inhibitor, implying that the proteasome machinery may be involved in the BCSG1-induced reduction of the BubR1 protein. Accompanied with a reduction of BubR1 protein level, BCSG1 expression resulted in multinucleation of breast cancer cells upon treatment with spindle inhibitor nocodazole, indicating an impaired mitotic checkpoint. Taken together, our novel findings suggest that BCSG1 may accelerate the progression of breast cancer at least in part by compromising the mitotic checkpoint control through inactivation of BubR1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576821     DOI: 10.1038/sj.onc.1206880

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  31 in total

1.  Expression of gamma-synuclein in colorectal cancer tissues and its role on colorectal cancer cell line HCT116.

Authors:  Qing Ye; Bo Feng; Yuan-Fei Peng; Xue-Hua Chen; Qu Cai; Bei-Qin Yu; Liang-Hui Li; Ming-Yuan Qiu; Bing-Ya Liu; Min-Hua Zheng
Journal:  World J Gastroenterol       Date:  2009-10-28       Impact factor: 5.742

2.  A peptide inhibitor of synuclein-γ reduces neovascularization of human endometriotic lesions.

Authors:  Andrew Kenneth Edwards; Sharanya Ramesh; Vinay Singh; Chandrakant Tayade
Journal:  Mol Hum Reprod       Date:  2014-07-14       Impact factor: 4.025

3.  The reciprocal regulation of gamma-synuclein and IGF-I receptor expression creates a circuit that modulates IGF-I signaling.

Authors:  Minjing Li; Yancun Yin; Hui Hua; Xiangming Sun; Ting Luo; Jiao Wang; Yangfu Jiang
Journal:  J Biol Chem       Date:  2010-07-29       Impact factor: 5.157

4.  SILAC-based proteomic analysis to investigate the impact of amyloid precursor protein expression in neuronal-like B103 cells.

Authors:  Dale Chaput; Lisa Hornbeck Kirouac; Harris Bell-Temin; Stanley M Stevens; Jaya Padmanabhan
Journal:  Electrophoresis       Date:  2012-12       Impact factor: 3.535

5.  Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Abigail D Winder; Kruti P Maniar; Jian-Jun Wei; Dachao Liu; Denise M Scholtens; John R Lurain; Julian C Schink; Barbara M Buttin; Virginia L Filiaci; Heather A Lankes; Nilsa C Ramirez; Kay Park; Meenakshi Singh; Richard W Lieberman; Robert S Mannel; Matthew A Powell; Floor J Backes; Cara A Mathews; Michael L Pearl; Angeles Alvarez Secord; David J Peace; David G Mutch; William T Creasman; J Julie Kim
Journal:  Cancer       Date:  2016-12-07       Impact factor: 6.860

6.  Insight into residues involved in the structure and function of the breast cancer associated protein human gamma synuclein.

Authors:  Panneerselvam Manivel; Jayaraman Muthukumaran; Muthu Kannan; Ramadas Krishna
Journal:  J Mol Model       Date:  2010-05-02       Impact factor: 1.810

7.  Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha.

Authors:  Yuenian Eric Shi; Yiding Chen; Raduwan Dackour; Louis Potters; Shui Wang; Qiang Ding; Zhaoyi Wang; Yiliang Ellie Liu
Journal:  Am J Pathol       Date:  2010-07-01       Impact factor: 4.307

8.  A novel conditional gene silencing method using a tumor-specific and heat-inducible siRNA system.

Authors:  Jing Feng; Xiaoyu Wang; Yi Liao; Jianguo Feng; Liling Tang
Journal:  J Ind Microbiol Biotechnol       Date:  2016-03-31       Impact factor: 3.346

9.  Synuclein gamma predicts poor clinical outcome in colon cancer with normal levels of carcinoembryonic antigen.

Authors:  Caiyun Liu; Bin Dong; Aiping Lu; Like Qu; Xiaofang Xing; Lin Meng; Jian Wu; Y Eric Shi; Chengchao Shou
Journal:  BMC Cancer       Date:  2010-07-07       Impact factor: 4.430

10.  Synuclein gamma protects HER2 and renders resistance to Hsp90 disruption.

Authors:  Yongfeng Shao; Bingchan Wang; Dorothy Shi; Suyu Miao; Panneerselvam Manivel; Ramadas Krishna; Yiding Chen; Y Eric Shi
Journal:  Mol Oncol       Date:  2014-06-14       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.